Without secure upstream API and 6-APA production, the United States does not have true antibiotic supply security. With the right policy framework and close coordination with European partners, we can rebuild domestic capacity, strengthen allied production, and secure essential medicines for the long term.
The findings reinforce a persistent pattern in global solar trade: when enforcement actions target specific countries, production and shipments shift to new jurisdictions.
Revoking PNTR for China would move Chinese imports onto an average effective Column 2 tariff rate of 38.9 percent, helping rebalance trade, restore domestic production capacity, and reduce strategic dependence on an increasingly adversarial economic system.
CPA welcomes new proposals from the Food and Drug Administration (FDA) aimed at rebuilding domestic generic drug manufacturing, strengthening oversight of foreign pharmaceutical production, and improving supply chain transparency.
The report finds that the CPA Domestic Market Share Index (DMSI) – which measures the share of U.S. demand served by domestic producers – rebounded in 2025 as Section 232 tariffs and other industrial policies began to reshape the competitive landscape for American industry.
Suniva’s expansion highlights the critical importance of rebuilding the domestic crystalline silicon photovoltaic (PV) supply chain—particularly solar cell manufacturing, one of the most strategically important segments of U.S. energy production.
The investment is clear evidence that U.S. trade policy is driving a resurgence in domestic production and job creation. This new investment underscores Whirlpool Corp.’s long-standing commitment to the U.S. market and creating high-quality American jobs.
Section 232 tariffs remain a cornerstone of U.S. industrial policy, particularly in sectors tied to infrastructure, energy, and defense. This proclamation reinforces their role as a long-term tool to increase domestic capacity utilization, reduce import dependence, and support a resilient industrial base.
Today’s action is a meaningful step toward restoring America’s ability to produce critical pharmaceuticals and APIs.
America’s healthcare system cannot remain dependent on fragile and subsidized foreign supply chains for generic pharmaceuticals and other critical countermeasures that are fundamental to patient care.
